BioCentury | Aug 2, 2010
Clinical News

Simcor Niacin/simvastatin regulatory update

...FDA approved new dosage strengths of Abbott's Simcor, a fixed-dose combination of extended-release niacin and immediate-release...
...will be made available this month, are 500/40 mg and 1000/40 mg. FDA originally approved Simcor...
...its 2008 acquisition of Kos Pharmaceuticals Inc. Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Simcor Niacin/simvastatin...
BioCentury | Dec 21, 2009
Clinical News

Simcor niacin/simvastatin regulatory update

...Abbott submitted an sNDA to FDA for 500/40 and 1000/40 mg dosage strengths of Simcor niacin...
...approved 500/20, 750/20 and 1000/20 mg strengths of Simcor last year. Abbott gained rights to Simcor...
...Kos Pharmaceuticals (see BioCentury, Jan. 1, 2008). Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Simcor niacin/simvastatin...
BioCentury | Jan 12, 2009
Finance

New products to watch

...Selected drugs that received regulatory approval in 2008. Company Product Indication 2008 approval Abbott (NYSE:ABT) Simcor...
BioCentury | Aug 14, 2008
Distillery Therapeutics

This Week in Therapeutics

...Researchers declined to disclose next steps. Merck & Co. Inc. markets cholesterol drug Zocor simvastatin. Simcor...
BioCentury | Apr 7, 2008
Finance

1Q approvals/1Q setbacks

...approvals/1Q setbacks 1Q approvals Selected first quarter product approvals. Company Approval Abbott (NYSE:ABT) FDA approves Simcor...
BioCentury | Feb 18, 2008
Clinical News

Simcor niacin/simvastatin regulatory update

...FDA approved an NDA from Abbott for Simcor, a fixed-dose combination of extended-release Niaspan niacin and...
...lipid disease when treatment with either agent alone was not adequate. Abbott gained rights to Simcor...
...Kos Pharmaceuticals Inc. (see BioCentury, Jan. 1). Abbott Laboratories (NYSE:ABT), Abbott Park, Ill. Product: Simcor niacin/simvastatin...
BioCentury | Feb 16, 2008
Company News

FDA approves Abbott's Simcor

...FDA approved an NDA from Abbott (NYSE:ABT) for Simcor , a fixed-dose combination of extended-release niacin...
...rights to Simcor through its acquisition of Kos . Solvay (Euronext:SOLB) has rights to co-promote Simcor...
BioCentury | Nov 12, 2007
Clinical News

Simcor niacin/simvastatin: Phase III data

...In the double-blind Phase III SEACOAST trial in >600 patients, Simcor met the primary endpoint of...
...Brussels, Belgium), which has rights to co-promote Simcor in the U.S. ABT gained rights to Simcor...
...Kos Pharmaceuticals Inc. (see BioCentury, Jan. 1). Abbott Laboratories (ABT), Abbott Park, Ill. Product: Simcor niacin/simvastatin...
BioCentury | Nov 6, 2007
Clinical News

Abbott presents Simcor results

...ABT said Simcor met the primary endpoint of a significant reduction in non-HDL cholesterol vs. simvastatin...
...were presented at the American Heart Association meeting in Orlando. ABT submitted an NDA for Simcor...
...Solvay (Euronext:SOLB), which has rights to co-promote Simcor in the U.S. ABT gained rights to Simcor...
BioCentury | Oct 29, 2007
Company News

Abbott, Solvay sales and marketing update

...SOLB received rights to co-promote ABT's Simcor in the U.S. to manage cholesterol levels. ABT submitted...
...the indication. The companies hope to launch the drug in 1H08. ABT gained rights to Simcor...
Items per page:
1 - 10 of 11